Positive Phase III data for ‘Antibody Cocktail’ REGN-COV2
Phase III data (n=799) demonstrated greater reduction in primary endpoint, mean daily change in viral load through day 7 in pts with high viral load treated with REGN-COV2 vs placebo (p<0.0001); with a 57% reduction in COVID-19-related medical visits through day 29 (p=0.024).
Source:
Biospace Inc.
SPS commentary:
REGN-COV2 is an investigational COVID-19 antibody cocktail consisting of two non-competing antibodies that bind non-competitively to the receptor binding domain of spike protein on the SARS-CoV-2 virus.